Citations (23)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Elżbieta Iskierka-Jażdżewska, Federico Canzian, Anna Stępień, Alessandro Martino, Daniele Campa, Angelica Stein, Małgorzata Krawczyk-Kuliś, Malwina Rybicka-Ramos, Sławomira Kyrcz-Krzemień, Aleksandra Butrym, Grzegorz Mazur, Artur Jurczyszyn, Daria Zawirska, Norbert Grząśko, Waldemar Tomczak, Edyta Subocz, Marzena Wątek, Marcin Pasiarski, Marcin Rymko, Małgorzata Całbecka, Agnieszka Druzd-Sitek, Jan Walewski, Marcin Kruszewski, Małgorzata Raźny, Jan Maciej Zaucha, Marek Dudziński, Paweł Gaj, Tadeusz Robak, Krzysztof Warzocha & Krzysztof Jamroziak. (2020) Cereblon (CRBN) gene polymorphisms predict clinical response and progression-free survival in relapsed/refractory multiple myeloma patients treated with lenalidomide: a pharmacogenetic study from the IMMEnSE consortium. Leukemia & Lymphoma 61:3, pages 699-706.
Read now
Read now
Rachel E. Hayden, Guy Pratt, Claudia Roberts, Mark T. Drayson & Chris M. Bunce. (2012) Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches. Leukemia & Lymphoma 53:4, pages 537-549.
Read now
Read now
Krzysztof Giannopoulos, Daniel Mertens & Stephan Stilgenbauer. (2011) Treating chronic lymphocytic leukemia with thalidomide and lenalidomide. Expert Opinion on Pharmacotherapy 12:18, pages 2857-2864.
Read now
Read now
Chadi Nabhan, Neil Dalal, Jayesh Mehta & Neil E. Kay. (2011) Biologic agent activity in chronic lymphocytic leukemia: a framework for future therapies. Leukemia & Lymphoma 52:3, pages 374-386.
Read now
Read now
Articles from other publishers (19)
Hyoung Kyu Kim, Jung Eun Seol, Sang Woo Ahn, Seungje Jeon, Chul-Seung Park & Jin Han. (2021) Cereblon: promise and challenges for combating human diseases. Pflügers Archiv - European Journal of Physiology 473:11, pages 1695-1711.
Crossref
Crossref
Ying Ying Keng, Kiam Heong Kwa & Kurunathan Ratnavelu. (2021) Centrality analysis in a drug network and its application to drug repositioning. Applied Mathematics and Computation 395, pages 125870.
Crossref
Crossref
Shanmugapriya Thangavadivel, Qiuhong Zhao, Narendranath Epperla, Lindsey Rike, Xiaokui Mo, Mohamed Badawi, Darlene M. Bystry, Mitch A. Phelps, Leslie A. Andritsos, Kerry A. Rogers, Jeffrey Jones, Jennifer A. Woyach, John C. Byrd & Farrukh T. Awan. (2020) Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic Leukemia. Clinical Cancer Research 26:23, pages 6187-6195.
Crossref
Crossref
Ota Fuchs. (2019) Treatment of Lymphoid and Myeloid Malignancies by Immunomodulatory Drugs. Cardiovascular & Hematological Disorders-Drug Targets 19:1, pages 51-78.
Crossref
Crossref
Ming Li, Yuxia Wang, Jianying Zhang, Songqiang Xie, Chaojie Wang & Yingliang Wu. (2016) Synthesis and Biological Evaluation of Novel Aromatic Imide-Polyamine Conjugates. Molecules 21:12, pages 1637.
Crossref
Crossref
Hyoung Kyu Kim, Tae Hee Ko, Bayalagmaa Nyamaa, Sung Ryul Lee, Nari Kim, Kyung Soo Ko, Byoung Doo Rhee, Chul-Seung Park, Bernd Nilius & Jin Han. (2016) Cereblon in health and disease. Pflügers Archiv - European Journal of Physiology 468:8, pages 1299-1309.
Crossref
Crossref
Leticia Huergo-Zapico, Andrea Acebes-Huerta, Ana Pilar Gonzalez-Rodriguez, Juan Contesti, Esther Gonzalez-García, Angel R. Payer, Monica Villa-Alvarez, Azahara Fernández-Guizán, Alejandro López-Soto & Segundo Gonzalez. (2014) Expansion of NK Cells and Reduction of NKG2D Expression in Chronic Lymphocytic Leukemia. Correlation with Progressive Disease. PLoS ONE 9:10, pages e108326.
Crossref
Crossref
Andrea Acebes-Huerta, Leticia Huergo-Zapico, Ana Pilar Gonzalez-Rodriguez, Azahara Fernandez-Guizan, Angel R. Payer, Alejandro L?pez-Soto & Segundo Gonzalez. (2014) Lenalidomide Induces Immunomodulation in Chronic Lymphocytic Leukemia and Enhances Antitumor Immune Responses Mediated by NK and CD4 T Cells. BioMed Research International 2014, pages 1-11.
Crossref
Crossref
Domenico Ribatti. (2013) Angiogenesis as a treatment target in leukemia. International Journal of Hematologic Oncology 2:3, pages 229-242.
Crossref
Crossref
Yi Xia, Rui-Nan Lu & Jianyong Li. (2012) Angiogenic factors in chronic lymphocytic leukemia. Leukemia Research 36:10, pages 1211-1217.
Crossref
Crossref
Anja Troeger, Amy J. Johnson, Jenna WoodWilliam G. Blum, Leslie A. Andritsos, John C. Byrd & David A. Williams. (2012) RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans. Blood 119:20, pages 4708-4718.
Crossref
Crossref
Nianhang Chen, Lian Wen, Henry Lau, Sekhar Surapaneni & Gondi Kumar. (2011) Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects. Cancer Chemotherapy and Pharmacology 69:3, pages 789-797.
Crossref
Crossref
Jessica M. McDaniel, Javier Pinilla-Ibarz & P. K. Epling-Burnette. (2012) Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies. Advances in Hematology 2012, pages 1-9.
Crossref
Crossref
Tamara Miner Haygood, Edith M. Marom & Donna M. Weber. 2012. Oncologic Imaging: A Multidisciplinary Approach. Oncologic Imaging: A Multidisciplinary Approach
509
529
.
Arvind Arumainathan, Nagesh Kalakonda & Andrew R. Pettitt. (2011) Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p. European Journal of Haematology 87:4, pages 372-375.
Crossref
Crossref
C. Patrick Reynolds, Min H. Kang, Stephen T. Keir, Richard Gorlick, E. Anders Kolb, Richard Lock, John M. Maris, Hernan Carol, Christopher L. Morton, Catherine A. Billups, Malcolm A. Smith & Peter J. Houghton. (2011) Initial testing of lenalidomide by the pediatric preclinical testing program. Pediatric Blood & Cancer 57:4, pages 606-611.
Crossref
Crossref
Mathieu Wémeau, Jordan Gauthier, Xavier Leleu & Ibrahim Yakoub-Agha. (2011) IMiD en hématologie. Bulletin du Cancer 98:8, pages 879-887.
Crossref
Crossref
Andrea Schnaiter & Stephan Stilgenbauer. (2011) Novel targeted treatment strategies for refractory chronic lymphocytic leukaemia. Therapeutic Advances in Hematology 2:4, pages 249-265.
Crossref
Crossref
Sarah E. M. HermanRosa LapalombellaAmber L. GordonAsha RamanunniKristie A. BlumJeffrey JonesXiaoli ZhangBrian J. Lannutti, Kamal D. Puri, Natarajan MuthusamyJohn C. Byrd & Amy J. Johnson. (2011) The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood 117:16, pages 4323-4327.
Crossref
Crossref